Company: ARMP
Filing Date: 2025-12-01
Form Type: 424B5
Source: 0001104659-25-117382
Chunk: 52

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-12-01
Form: 424B5
Chunk 52
---
-outstanding preferred stock, the holders of common stock are entitled to receive dividends, if any, as may
be declared from time to time by our board of directors out of legally available funds.

Liquidation

In the event of our liquidation,
dissolution or winding-up, holders of our common stock will be entitled to share ratably in the net assets legally available for distribution
to shareholders after the payment of all our debts and other liabilities, subject to the satisfaction of any liquidation preference granted
to the holders of any outstanding shares of preferred stock.

Rightsand Preferences

Holders of our common stock
have no preemptive, conversion or subscription rights, and there is no redemption or sinking fund provisions applicable to our common
stock. The rights, preferences and privileges of the holders of our common stock are subject to, and may be adversely affected by, the
rights of the holders of shares of any series of our preferred stock that are outstanding or that we may designate and issue in the future.

Fully Paid and Nonassessable

All of our outstanding shares
of common stock are, and the shares of common stock to be issued in any offering under this prospectus will be, fully paid and nonassessable.

Preferred Stock

Our board of directors has
the authority, without further action by the shareholders, to issue up to 10,000,000 shares of preferred stock in one or more series,
to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges
of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon and to increase or decrease the
number of shares of any such series, but not below the number of shares of such series then outstanding.

<div align='center'>15</div>

Our board of directors may
authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights
of the holders of the common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions
and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in our control
that may otherwise benefit holders of our common stock and may adversely affect the market price of the common stock and the voting and
other rights of the holders of common stock.

There currently are no provisions
under our amended and restated articles of incorporation or under any other contractual obligations whereby we are required to issue or